{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:47:29Z","timestamp":1790790449308,"version":"4.1.0"},"reference-count":59,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,1,1]]},"DOI":"10.1001\/jamadermatol.2021.4812","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T16:01:01Z","timestamp":1638979261000},"page":"51","source":"Crossref","is-referenced-by-count":27,"title":["Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma"],"prefix":"10.1001","volume":"158","author":[{"given":"Shayan","family":"Cheraghlou","sequence":"first","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Ugwu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Girardi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"doi210065r1","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/archderm.1980.01640310043015","article-title":"Acral lentiginous melanoma.","volume":"116","author":"Coleman","year":"1980","journal-title":"Arch Dermatol"},{"issue":"19","key":"doi210065r3","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"doi210065r4","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"doi210065r5","doi-asserted-by":"publisher","first-page":"v533","DOI":"10.1093\/annonc\/mdz255","article-title":"Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III\/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial.","volume":"30","author":"Weber","year":"2019","journal-title":"Ann Oncol."},{"issue":"19","key":"doi210065r6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma.","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"33","key":"doi210065r7","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial.","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"doi210065r8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1067\/mjd.2003.63","article-title":"Acral lentiginous melanoma mimicking benign disease: the Emory experience.","volume":"48","author":"Soon","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"doi210065r9","first-page":"1990","article-title":"Acral lentiginous melanoma\u2014misdiagnosis, referral delay and 5 years specific survival according to site.","volume":"18","author":"Boriani","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"doi210065r10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1757-1146-1-11","article-title":"Acral lentiginous melanoma of the foot and ankle: a case series and review of the literature.","volume":"1","author":"Bristow","year":"2008","journal-title":"J Foot Ankle Res"},{"issue":"3","key":"doi210065r11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjd.2006.155.issue-3","article-title":"Acral lentiginous melanoma: a clinicoprognostic study of 126 cases.","volume":"155","author":"Phan","year":"2006","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi210065r12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","article-title":"Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.","volume":"145","author":"Bradford","year":"2009","journal-title":"Arch Dermatol"},{"issue":"2","key":"doi210065r13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00000478-197706000-00004","article-title":"Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma.","volume":"1","author":"Arrington","year":"1977","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"doi210065r14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bjd.2017.177.issue-2","article-title":"Prognostic factors and survival in acral lentiginous melanoma.","volume":"177","author":"Asgari","year":"2017","journal-title":"Br J Dermatol"},{"issue":"20","key":"doi210065r15","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma.","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"doi210065r16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jdermsci.2013.07.013","article-title":"KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.","volume":"72","author":"Zebary","year":"2013","journal-title":"J Dermatol Sci"},{"issue":"11","key":"doi210065r17","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/modpathol.2009.116","article-title":"Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous\/mucosal type.","volume":"22","author":"Torres-Cabala","year":"2009","journal-title":"Mod Pathol"},{"issue":"2","key":"doi210065r18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/exd.12080","article-title":"Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.","volume":"22","author":"Puig-Butill\u00e9","year":"2013","journal-title":"Exp Dermatol"},{"key":"doi210065r19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jss.2020.02.010","article-title":"Acral lentiginous melanoma: incidence and survival in the United States, 2006-2015, an analysis of the SEER registry.","volume":"251","author":"Huang","year":"2020","journal-title":"J Surg Res"},{"issue":"8","key":"doi210065r20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/jso.v119.8","article-title":"Does sentinel lymph node status have prognostic significance in patients with acral lentiginous melanoma?","volume":"119","author":"Pavri","year":"2019","journal-title":"J Surg Oncol"},{"issue":"1","key":"doi210065r21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jaad.2014.10.008","article-title":"Acral lentiginous melanoma: who benefits from sentinel lymph node biopsy?","volume":"72","author":"Ito","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi210065r22","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.amjsurg.2012.05.013","article-title":"Unique prognostic factors in acral lentiginous melanoma.","volume":"204","author":"Egger","year":"2012","journal-title":"Am J Surg"},{"issue":"7","key":"doi210065r23","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jamadermatol.2016.0875","article-title":"Acral lentiginous histologic subtype and sentinel lymph node positivity in thin melanoma.","volume":"152","author":"Marek","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi210065r24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"doi210065r25","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1245\/s10434-019-07213-1","article-title":"Incident cases captured in the National Cancer Database compared with those in U.S. Population Based Central Cancer Registries in 2012-2014.","volume":"26","author":"Mallin","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"doi210065r26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jaad.2018.10.026","article-title":"Treatment of primary nonmetastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival.","volume":"80","author":"Cheraghlou","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi210065r27","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jaad.2016.01.024","article-title":"Characteristics, treatment, and survival of invasive malignant melanoma (MM) in giant pigmented nevi (GPN) in adults: 976 cases from the National Cancer Data Base (NCDB).","volume":"74","author":"Turkeltaub","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"doi210065r28","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/jso.25090","article-title":"Merkel cell carcinoma: clinical outcome and prognostic factors in 351 patients.","volume":"117","author":"van Veenendaal","year":"2018","journal-title":"J Surg Oncol"},{"key":"doi210065r29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2019.08.058","article-title":"The impact of facility characteristics on Merkel cell carcinoma outcomes: a retrospective cohort study.","author":"Cheraghlou","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"doi210065r30","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1245\/s10434-015-4672-3","article-title":"Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB).","volume":"22","author":"Asare","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"doi210065r32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/CMR.0b013e32833ba9ff","article-title":"Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma.","volume":"20","author":"Kunte","year":"2010","journal-title":"Melanoma Res"},{"issue":"3","key":"doi210065r33","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/JCO.1999.17.3.976","article-title":"Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.","volume":"17","author":"Gershenwald","year":"1999","journal-title":"J Clin Oncol"},{"issue":"6","key":"doi210065r34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1245\/ASO.2005.04.027","article-title":"Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.","volume":"12","author":"Kesmodel","year":"2005","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"doi210065r35","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00268-005-7736-x","article-title":"Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up.","volume":"29","author":"Leong","year":"2005","journal-title":"World J Surg"},{"issue":"8","key":"doi210065r36","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1001\/archderm.134.8.983","article-title":"Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma.","volume":"134","author":"Mraz-Gernhard","year":"1998","journal-title":"Arch Dermatol"},{"issue":"9","key":"doi210065r37","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw042","article-title":"Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: survival analyses of 6908 cases from the National Cancer Data Base.","volume":"108","author":"Bhatia","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"doi210065r38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1245\/ASO.2004.03.044","article-title":"Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model.","volume":"11","author":"Sondak","year":"2004","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"doi210065r39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/(ISSN)1097-0142","article-title":"The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.","volume":"109","author":"Paek","year":"2007","journal-title":"Cancer"},{"issue":"6900","key":"doi210065r40","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/418823a","article-title":"A progression puzzle.","volume":"418","author":"Bernards","year":"2002","journal-title":"Nature"},{"issue":"12","key":"doi210065r41","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0046-8177(84)80310-X","article-title":"A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma.","volume":"15","author":"Clark","year":"1984","journal-title":"Hum Pathol"},{"issue":"19","key":"doi210065r42","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/onc.2013.194","article-title":"Melanoma metastasis: new concepts and evolving paradigms.","volume":"33","author":"Damsky","year":"2014","journal-title":"Oncogene"},{"issue":"4","key":"doi210065r43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000063354","article-title":"Is subungual melanoma related to trauma?","volume":"204","author":"M\u00f6hrle","year":"2002","journal-title":"Dermatology"},{"issue":"1","key":"doi210065r44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1023\/A:1008872014889","article-title":"A case-control study of melanomas of the soles and palms (Australia and Scotland).","volume":"10","author":"Green","year":"1999","journal-title":"Cancer Causes Control"},{"issue":"11","key":"doi210065r45","first-page":"1051","article-title":"Controversies in acral lentiginous melanoma.","volume":"28","author":"Stalkup","year":"2002","journal-title":"Dermatol Surg"},{"issue":"7","key":"doi210065r46","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamadermatol.2021.0793","article-title":"A mutational survey of acral nevi.","volume":"157","author":"Smalley","year":"2021","journal-title":"JAMA Dermatol"},{"key":"doi210065r47","doi-asserted-by":"crossref","DOI":"10.1111\/pcmr.12999","article-title":"Acral lentiginous melanoma-population, treatment, and survival using the NCDB from 2004 to 2015.","author":"Bian","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"doi210065r48","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.jaad.2011.05.030","article-title":"Melanoma survival in the United States, 1992 to 2005.","volume":"65","author":"Pollack","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi210065r49","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.","volume":"78","author":"Barnhill","year":"1996","journal-title":"Cancer"},{"issue":"5","key":"doi210065r50","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1016\/j.jcms.2013.09.007","article-title":"Value of anatomic site, histology and clinicopathological parameters for prediction of lymph node metastasis and overall survival in head and neck melanomas.","volume":"42","author":"Ettl","year":"2014","journal-title":"J Craniomaxillofac Surg"},{"issue":"12","key":"doi210065r51","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1001\/archderm.142.12.1551","article-title":"Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas.","volume":"142","author":"Liu","year":"2006","journal-title":"Arch Dermatol"},{"issue":"4","key":"doi210065r52","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jaad.2012.09.047","article-title":"Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia.","volume":"68","author":"Mar","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"doi210065r53","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1200\/JCO.19.02362","article-title":"Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the Melanoma Institute Australia Nomogram.","volume":"38","author":"Lo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"doi210065r54","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaad.2020.03.053","article-title":"Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.","volume":"83","author":"Greenhaw","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"doi210065r55","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/PO.19.00206","article-title":"Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma.","volume":"4","author":"Bellomo","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"doi210065r56","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12885-018-4016-3","article-title":"Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.","volume":"18","author":"Zager","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"doi210065r57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0379-6","article-title":"A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.","volume":"10","author":"Zhang","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"5","key":"doi210065r58","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jaad.2015.01.009","article-title":"Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.","volume":"72","author":"Gerami","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi210065r59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res"},{"key":"doi210065r31","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"doi210065r2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma (Version 2.2021). Accessed July 7, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2786976\/jamadermatology_cheraghlou_2021_oi_210065_1641397657.81411.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T16:02:38Z","timestamp":1642608158000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2786976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.4812","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}